Antihemophilic Factor Drug - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509241009

Publication Date:

September 6, 2024

Pages:

130

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Antihemophilic Factor Drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to prevent bleeding.
The global market for Antihemophilic Factor Drug was estimated to be worth US$ 541 million in 2023 and is forecast to a readjusted size of US$ 796 million by 2030 with a CAGR of 6.1% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antihemophilic Factor Drug, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Antihemophilic Factor Drug by region & country, by Type, and by Application.
The Antihemophilic Factor Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihemophilic Factor Drug.
麻豆原创 Segmentation
By Company
Bayer
Takeda
Novo Nordisk
Pfizer
Grifols
CSL Behring
Sanofi
Cigna
Octapharma
GC Pharma
Hualan Biological Engineering
Shanghai RAAS blood products
Segment by Type:
250 IU
500 IU
1000 IU
1500 IU
2000 IU
3000 IU
4000 IU
Other potencies
Segment by Application
Adult
Pediatric
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Antihemophilic Factor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Antihemophilic Factor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Antihemophilic Factor Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Antihemophilic Factor Drug Product Introduction
1.2 Global Antihemophilic Factor Drug 麻豆原创 Size Forecast
1.2.1 Global Antihemophilic Factor Drug Sales Value (2019-2030)
1.2.2 Global Antihemophilic Factor Drug Sales Volume (2019-2030)
1.2.3 Global Antihemophilic Factor Drug Sales Price (2019-2030)
1.3 Antihemophilic Factor Drug 麻豆原创 Trends & Drivers
1.3.1 Antihemophilic Factor Drug Industry Trends
1.3.2 Antihemophilic Factor Drug 麻豆原创 Drivers & Opportunity
1.3.3 Antihemophilic Factor Drug 麻豆原创 Challenges
1.3.4 Antihemophilic Factor Drug 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Antihemophilic Factor Drug Players Revenue Ranking (2023)
2.2 Global Antihemophilic Factor Drug Revenue by Company (2019-2024)
2.3 Global Antihemophilic Factor Drug Players Sales Volume Ranking (2023)
2.4 Global Antihemophilic Factor Drug Sales Volume by Company Players (2019-2024)
2.5 Global Antihemophilic Factor Drug Average Price by Company (2019-2024)
2.6 Key Manufacturers Antihemophilic Factor Drug Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Antihemophilic Factor Drug Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Antihemophilic Factor Drug
2.9 Antihemophilic Factor Drug 麻豆原创 Competitive Analysis
2.9.1 Antihemophilic Factor Drug 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Antihemophilic Factor Drug Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihemophilic Factor Drug as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 250 IU
3.1.2 500 IU
3.1.3 1000 IU
3.1.4 1500 IU
3.1.5 2000 IU
3.1.6 3000 IU
3.1.7 4000 IU
3.1.8 Other potencies
3.2 Global Antihemophilic Factor Drug Sales Value by Type
3.2.1 Global Antihemophilic Factor Drug Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Antihemophilic Factor Drug Sales Value, by Type (2019-2030)
3.2.3 Global Antihemophilic Factor Drug Sales Value, by Type (%) (2019-2030)
3.3 Global Antihemophilic Factor Drug Sales Volume by Type
3.3.1 Global Antihemophilic Factor Drug Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Antihemophilic Factor Drug Sales Volume, by Type (2019-2030)
3.3.3 Global Antihemophilic Factor Drug Sales Volume, by Type (%) (2019-2030)
3.4 Global Antihemophilic Factor Drug Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Adult
4.1.2 Pediatric
4.2 Global Antihemophilic Factor Drug Sales Value by Application
4.2.1 Global Antihemophilic Factor Drug Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Antihemophilic Factor Drug Sales Value, by Application (2019-2030)
4.2.3 Global Antihemophilic Factor Drug Sales Value, by Application (%) (2019-2030)
4.3 Global Antihemophilic Factor Drug Sales Volume by Application
4.3.1 Global Antihemophilic Factor Drug Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Antihemophilic Factor Drug Sales Volume, by Application (2019-2030)
4.3.3 Global Antihemophilic Factor Drug Sales Volume, by Application (%) (2019-2030)
4.4 Global Antihemophilic Factor Drug Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Antihemophilic Factor Drug Sales Value by Region
5.1.1 Global Antihemophilic Factor Drug Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Antihemophilic Factor Drug Sales Value by Region (2019-2024)
5.1.3 Global Antihemophilic Factor Drug Sales Value by Region (2025-2030)
5.1.4 Global Antihemophilic Factor Drug Sales Value by Region (%), (2019-2030)
5.2 Global Antihemophilic Factor Drug Sales Volume by Region
5.2.1 Global Antihemophilic Factor Drug Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Antihemophilic Factor Drug Sales Volume by Region (2019-2024)
5.2.3 Global Antihemophilic Factor Drug Sales Volume by Region (2025-2030)
5.2.4 Global Antihemophilic Factor Drug Sales Volume by Region (%), (2019-2030)
5.3 Global Antihemophilic Factor Drug Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Antihemophilic Factor Drug Sales Value, 2019-2030
5.4.2 North America Antihemophilic Factor Drug Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Antihemophilic Factor Drug Sales Value, 2019-2030
5.5.2 Europe Antihemophilic Factor Drug Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Antihemophilic Factor Drug Sales Value, 2019-2030
5.6.2 Asia Pacific Antihemophilic Factor Drug Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Antihemophilic Factor Drug Sales Value, 2019-2030
5.7.2 South America Antihemophilic Factor Drug Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Antihemophilic Factor Drug Sales Value, 2019-2030
5.8.2 Middle East & Africa Antihemophilic Factor Drug Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Antihemophilic Factor Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Antihemophilic Factor Drug Sales Value
6.2.1 Key Countries/Regions Antihemophilic Factor Drug Sales Value, 2019-2030
6.2.2 Key Countries/Regions Antihemophilic Factor Drug Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Antihemophilic Factor Drug Sales Value, 2019-2030
6.3.2 United States Antihemophilic Factor Drug Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Antihemophilic Factor Drug Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Antihemophilic Factor Drug Sales Value, 2019-2030
6.4.2 Europe Antihemophilic Factor Drug Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Antihemophilic Factor Drug Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Antihemophilic Factor Drug Sales Value, 2019-2030
6.5.2 China Antihemophilic Factor Drug Sales Value by Type (%), 2023 VS 2030
6.5.3 China Antihemophilic Factor Drug Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Antihemophilic Factor Drug Sales Value, 2019-2030
6.6.2 Japan Antihemophilic Factor Drug Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Antihemophilic Factor Drug Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Antihemophilic Factor Drug Sales Value, 2019-2030
6.7.2 South Korea Antihemophilic Factor Drug Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Antihemophilic Factor Drug Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Antihemophilic Factor Drug Sales Value, 2019-2030
6.8.2 Southeast Asia Antihemophilic Factor Drug Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Antihemophilic Factor Drug Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Antihemophilic Factor Drug Sales Value, 2019-2030
6.9.2 India Antihemophilic Factor Drug Sales Value by Type (%), 2023 VS 2030
6.9.3 India Antihemophilic Factor Drug Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Bayer
7.1.1 Bayer Company Information
7.1.2 Bayer Introduction and Business Overview
7.1.3 Bayer Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Bayer Antihemophilic Factor Drug Product Offerings
7.1.5 Bayer Recent Development
7.2 Takeda
7.2.1 Takeda Company Information
7.2.2 Takeda Introduction and Business Overview
7.2.3 Takeda Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Takeda Antihemophilic Factor Drug Product Offerings
7.2.5 Takeda Recent Development
7.3 Novo Nordisk
7.3.1 Novo Nordisk Company Information
7.3.2 Novo Nordisk Introduction and Business Overview
7.3.3 Novo Nordisk Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Novo Nordisk Antihemophilic Factor Drug Product Offerings
7.3.5 Novo Nordisk Recent Development
7.4 Pfizer
7.4.1 Pfizer Company Information
7.4.2 Pfizer Introduction and Business Overview
7.4.3 Pfizer Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Pfizer Antihemophilic Factor Drug Product Offerings
7.4.5 Pfizer Recent Development
7.5 Grifols
7.5.1 Grifols Company Information
7.5.2 Grifols Introduction and Business Overview
7.5.3 Grifols Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Grifols Antihemophilic Factor Drug Product Offerings
7.5.5 Grifols Recent Development
7.6 CSL Behring
7.6.1 CSL Behring Company Information
7.6.2 CSL Behring Introduction and Business Overview
7.6.3 CSL Behring Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
7.6.4 CSL Behring Antihemophilic Factor Drug Product Offerings
7.6.5 CSL Behring Recent Development
7.7 Sanofi
7.7.1 Sanofi Company Information
7.7.2 Sanofi Introduction and Business Overview
7.7.3 Sanofi Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Sanofi Antihemophilic Factor Drug Product Offerings
7.7.5 Sanofi Recent Development
7.8 Cigna
7.8.1 Cigna Company Information
7.8.2 Cigna Introduction and Business Overview
7.8.3 Cigna Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Cigna Antihemophilic Factor Drug Product Offerings
7.8.5 Cigna Recent Development
7.9 Octapharma
7.9.1 Octapharma Company Information
7.9.2 Octapharma Introduction and Business Overview
7.9.3 Octapharma Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Octapharma Antihemophilic Factor Drug Product Offerings
7.9.5 Octapharma Recent Development
7.10 GC Pharma
7.10.1 GC Pharma Company Information
7.10.2 GC Pharma Introduction and Business Overview
7.10.3 GC Pharma Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
7.10.4 GC Pharma Antihemophilic Factor Drug Product Offerings
7.10.5 GC Pharma Recent Development
7.11 Hualan Biological Engineering
7.11.1 Hualan Biological Engineering Company Information
7.11.2 Hualan Biological Engineering Introduction and Business Overview
7.11.3 Hualan Biological Engineering Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Hualan Biological Engineering Antihemophilic Factor Drug Product Offerings
7.11.5 Hualan Biological Engineering Recent Development
7.12 Shanghai RAAS blood products
7.12.1 Shanghai RAAS blood products Company Information
7.12.2 Shanghai RAAS blood products Introduction and Business Overview
7.12.3 Shanghai RAAS blood products Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Shanghai RAAS blood products Antihemophilic Factor Drug Product Offerings
7.12.5 Shanghai RAAS blood products Recent Development
8 Industry Chain Analysis
8.1 Antihemophilic Factor Drug Industrial Chain
8.2 Antihemophilic Factor Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Antihemophilic Factor Drug Sales Model
8.5.2 Sales Channel
8.5.3 Antihemophilic Factor Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Bayer
Takeda
Novo Nordisk
Pfizer
Grifols
CSL Behring
Sanofi
Cigna
Octapharma
GC Pharma
Hualan Biological Engineering
Shanghai RAAS blood products

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.